Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Large B-Cell, Diffuse 44Lymphoma, Mantle-Cell 30Lymphoma 28Lymphoma, Follicular 27Leukemia, Lymphocytic, Chronic, B-Cell 26Lymphoma, Non-Hodgkin 25Lymphoma, B-Cell, Marginal Zone 16Lymphoma, B-Cell 14Recurrence 12Burkitt Lymphoma 12Waldenstrom Macroglobulinemia 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Neoplasms 9Leukemia, Hairy Cell 5Lymphoproliferative Disorders 4Leukemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Hodgkin Disease 3beta-Thalassemia 2Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasm, Residual 2Lymphatic Diseases 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Biphenotypic, Acute 2Leukemia, B-Cell 2Infections 2Hematologic Neoplasms 2Epstein-Barr Virus Infections 2

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Classic Follicular Lymphoma × Rituximab × 90 days × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡